• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aptuit Founding CEO Resigns

Aptuit Founding CEO Resigns

August 28, 2008
CenterWatch Staff

Greenwich, Conn.-based Aptuit, a contract research organization (CRO), named Timothy (Tim) C. Tyson, a pharmaceutical industry veteran, as executive chairman and acting CEO, replacing Michael A. Griffith, the company’s founder and CEO since 2005. The company said Griffith resigned to pursue other opportunities.

“The Board wishes to thank Mike for his outstanding success in creating a world-class organization that is a trusted partner to hundreds of innovative clients throughout the world,” said Tony Ecock, outgoing chairman of Aptuit’s board of managers. “With 2,700 employees working with more than 800 clients throughout the world, Aptuit has established a solid foundation for continued growth and success.”

Since its founding, Aptuit grew quickly through acquisitions. A year ago, Aptuit acquired the chemical and pharmaceutical development business of German company Evotec AG for $63.9 million. Other acquisitions have included EaglePicher Pharmaceutical Services LLC, SSCI Inc., InfoPro Solutions, Almedica International and three business units of Quintiles.

Aptuit’s interim CEO, Tim Tyson, is the former COO, president and CEO of Valeant Pharmaceuticals International, where he served from 2002 through 2008. Prior to Valeant, Tyson’s pharmaceutical industry experience includes a 14-year tenure at GlaxoSmithKline, where he was president of Global Manufacturing and Supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals.

“Aptuit is uniquely positioned to help innovative partners create the new medicines of tomorrow, and we will work tirelessly to ensure that we do all that we can to help improve the way drugs are developed,” Tyson said.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing